Skip to Main content Skip to Navigation
Journal articles

Modeling favipiravir antiviral efficacy against emerging viruses: from animal studies to clinical trials

Abstract : In 2014, our research network was involved in the evaluation of favipiravir, an anti‐influenza polymerase inhibitor, against Ebola virus. In this review, we discuss how mathematical modeling was used, first to propose a relevant dosing regimen in humans, and then to optimize its antiviral efficacy in a nonhuman primate (NHP) model. The data collected in NHPs were finally used to develop a model of Ebola pathogenesis integrating the interactions among the virus, the innate and adaptive immune response, and the action of favipiravir. We conclude the review of this work by discussing how these results are of relevance for future human studies in the context of Ebola virus, but also for other emerging viral diseases for which no therapeutics are available.
Complete list of metadata

https://hal.archives-ouvertes.fr/hal-03131673
Contributor : Oskar Admin <>
Submitted on : Thursday, February 4, 2021 - 3:30:44 PM
Last modification on : Thursday, April 15, 2021 - 3:08:19 PM
Long-term archiving on: : Wednesday, May 5, 2021 - 7:08:23 PM

File

BPH_CPTPSP_2020_Madelain.pdf
Publisher files allowed on an open archive

Licence


Distributed under a Creative Commons Attribution - NonCommercial 4.0 International License

Identifiers

Citation

Vincent Madelain, France Mentré, Sylvain Baize, Xavier Anglaret, Cédric Laouénan, et al.. Modeling favipiravir antiviral efficacy against emerging viruses: from animal studies to clinical trials. CPT: Pharmacometrics and Systems Pharmacology, American Society for Clinical Pharmacology and Therapeutics ; International Society of Pharmacometrics, 2020, 9 (5), pp.258-271. ⟨10.1002/psp4.12510⟩. ⟨hal-03131673⟩

Share

Metrics

Record views

162

Files downloads

263